Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Emanuel P DeNoia"'
1
Akademický článek
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
Autor: Marie A. Printz, BA, Samuel S. Dychter, MD, Emanuel P. DeNoia, MD, Rena Harrigan, MPH, Barry J. Sugarman, PhD, Monica Zepeda, PhD, Jennifer Souratha, BSc, David W. Kang, BSc, Daniel C. Maneval, PhD
Publikováno v: Current Therapeutic Research, Vol 93, Iss , Pp 100604- (2020)
ABSTRACT: Background: Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/
Externí odkaz: https://doaj.org/article/9727f714ed4549758640d27883f0f639
Zobrazit plný text záznamu
2
Intraosseous vascular access using the EZ-IO can be safely maintained in the adult proximal humerus and proximal tibia for up to 48 h: Report of a clinical study
Autor: Chris Davlantes, Thomas Philbeck, Larry Miller, Tatiana Puga, Diana Montez, Emanuel P DeNoia
Publikováno v: The journal of vascular access. 23(3)
Background: Historically, intraosseous (IO) vascular access devices cleared to market by the US FDA have been restricted to 24-h use. An observational study was conducted to determine the safety of IO access for a period up to 48 h in adult volunteer
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f4b636fa6129b5378dd870f22431a75
https://pubmed.ncbi.nlm.nih.gov/33541218
Zobrazit plný text záznamu
3
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers
Autor: Daniel C. Maneval, David W. Kang, Marie A. Printz, Samuel S. Dychter, Barry J. Sugarman, Rena Harrigan, Monica L. Zepeda, Jennifer Souratha, Emanuel P. DeNoia
Publikováno v: Current Therapeutic Research, Clinical and Experimental
Current Therapeutic Research, Vol 93, Iss, Pp 100604-(2020)
Background Recombinant human hyaluronidase PH20 (rHuPH20) is used in subcutaneous formulations (eg, RITUXAN HYCELA [rituximab and hyaluronidase human], HERCEPTIN HYLECTA [trastuzumab and hyaluronidase-oysk], PHESGO [pertuzumab/trastuzumab/hyaluronida
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f288b82b197ef8fb713739350bf1fa9
http://europepmc.org/articles/PMC7490523
Zobrazit plný text záznamu
4
Tolerability and Pharmacokinetic Properties of Ondansetron Administered Subcutaneously With Recombinant Human Hyaluronidase in Minipigs and Healthy Volunteers
Autor: Rena Harrigan, Daniel Fellows, Emanuel P. DeNoia, Samuel S. Dychter, Daniel C. Maneval, Jesse Bahn, Barry J. Sugarman, Marie A. Printz, David B. Haughey
Publikováno v: Clinical Therapeutics. 36:211-224
Background Subcutaneous ondansetron facilitated by recombinant human hyaluronidase PH20 (rHuPH20) is an alternative for treating nausea/vomiting in patients who cannot receive ondansetron by other routes of administration. Objective Based on preclini
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::309c258e96eacf6f1215c07e1511be0d
https://doi.org/10.1016/j.clinthera.2013.12.013
Zobrazit plný text záznamu
5
Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation
Autor: Roy Eisenhandler, Diana M. Brainard, Marian Iwamoto, John A. Wagner, Julie A. Stone, Niresh Hariparsad, Alisha Norcross, Chengcheng Liu, Jared Lunceford, Amelia S. Petry, Larissa Wenning, Kelem Kassahun, Emanuel P. DeNoia
Publikováno v: The Journal of Clinical Pharmacology. 51:943-950
Raltegravir is an HIV-1 integrase strand transfer inhibitor with potent activity against HIV-1. A prior investigation of raltegravir coadministered with rifampin demonstrated a decrease in plasma concentrations of raltegravir likely secondary to indu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6670a3b2be161d29f0335edbcc2dae4
https://doi.org/10.1177/0091270010375959
Zobrazit plný text záznamu
6
Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation
Autor: Julie A. Stone, Eric Mangin, Alisha Rhoton, Keith Gottesdiener, Kalyan Ghosh, William D. Hanley, John A. Wagner, Matthew D. Troyer, Kelem Kassahun, Amelia S. Petry, Marian Iwamoto, Emanuel P. DeNoia, Ping Lu, Larissa Wenning
Publikováno v: The Journal of Clinical Pharmacology. 48:209-214
Raltegravir is a novel HIV-1 integrase inhibitor with potent in vitro activity (95% inhibitory concentration = 33 nM in 50% human serum). In vitro characterization of raltegravir inhibition potential was assessed against a panel of cytochrome P450 (C
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba459a8708ac091f233084d16b0db2f
https://doi.org/10.1177/0091270007310382
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje